Pharmacological strategies to enhance the response of hepatoblastoma to chemotherapy through MDR1 inhibition.
Saved in:
| Title: | Pharmacological strategies to enhance the response of hepatoblastoma to chemotherapy through MDR1 inhibition. |
|---|---|
| Authors: | Cives-Losada C; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain., Macias RIR; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain., Lozano E; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain., Zanatto L; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036, Barcelona, Spain., Sancho-Bru P; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.; Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, 08036, Barcelona, Spain., Martinez-Chantar ML; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.; Liver Disease Laboratory, Center for Cooperative Research in Biosciences (CICbioGUNE), Basque Research and Technology Alliance (BRTA), 48160, Derio, Spain., Avila MA; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.; Instituto de Investigaciones Sanitarias de Navarra IdiSNA, Hepatology Laboratory, Solid Tumors Program, CIMA, CCUN, University of Navarra, 31008, Pamplona, Spain., Armengol C; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain.; Childhood Liver Oncology Group, Translational Program in Cancer Research (CARE), Germans Trias i Pujol Research Institute (IGTP), 08916, Badalona, Spain., Cairo S; Champions Oncology, Rockville, MD, 20850, USA., Marin JJG; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain. jjgmarin@usal.es.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain. jjgmarin@usal.es., Briz O; Experimental Hepatology and Drug Targeting (HEVEPHARM), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, 37007, Salamanca, Spain. obriz@usal.es.; Center for the Study of Liver and Gastrointestinal Diseases (CIBEREHD), Carlos III National Institute of Health, 28029, Madrid, Spain. obriz@usal.es. |
| Source: | Acta pharmacologica Sinica [Acta Pharmacol Sin] 2026 Aug; Vol. 47 (8), pp. 2254-2267. Date of Electronic Publication: 2026 Apr 23. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: United States NLM ID: 100956087 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1745-7254 (Electronic) Linking ISSN: 16714083 NLM ISO Abbreviation: Acta Pharmacol Sin Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
